| Literature DB >> 27071072 |
Teun Bousema1,2, Gillian Stresman2, Amrish Y Baidjoe1, John Bradley3, Philip Knight4, William Stone1, Victor Osoti5, Euniah Makori5, Chrispin Owaga5, Wycliffe Odongo5, Pauline China5, Shehu Shagari5, Ogobara K Doumbo6, Robert W Sauerwein1, Simon Kariuki5, Chris Drakeley2, Jennifer Stevenson2,7, Jonathan Cox2.
Abstract
BACKGROUND: Malaria transmission is highly heterogeneous, generating malaria hotspots that can fuel malaria transmission across a wider area. Targeting hotspots may represent an efficacious strategy for reducing malaria transmission. We determined the impact of interventions targeted to serologically defined malaria hotspots on malaria transmission both inside hotspots and in surrounding communities. METHODS ANDEntities:
Mesh:
Substances:
Year: 2016 PMID: 27071072 PMCID: PMC4829260 DOI: 10.1371/journal.pmed.1001993
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Fig 1The study area in the highlands of western Kenya.
The study area comprised a 5 × 20 km rectangle in Rachuonyo South District, Nyanza Province.
Fig 2Spatial variation in malaria antibody prevalence and nPCR parasite prevalence in the study area in Rachuonyo South District during a community survey conducted in June–July 2011.
(A) Distribution of sampled compounds and variations in altitude across the study site (contour interval = 25 m). (B) Combined seroprevalence (for AMA-1 or MSP-119) for individual 250 × 250 m sub-cells and the location of 27 significant hotspots derived from spatial scan analysis of compound-level data. (C) The ten hotspots that were selected for the cluster-randomized trail, presented with evaluation zones. (D) The 27 serological hotspot locations are overlaid on a map of nPCR-detected malaria parasite prevalence for compounds consisting of >3 individuals.
Parasite prevalence and antibody prevalence in relation to age in the cross-sectional community survey in Rachuonyo South District in June–July 2011 that was conducted for hotspot detection.
| Age | nPCR Parasite Prevalence, Percent ( | Antibody Prevalence, Percent ( |
|---|---|---|
| ≤5 y | 21.2% (738/3,476) | 33.8% (1,501/4,437) |
| 6–10 y, | 26.1% (609/2,337) | 49.5% (1,483/2,994) |
| 11–15 y, | 24.8% (462/1,403) | 65.1% (1,559/2,396) |
| 16–25 y | 19.2% (374/1,574) | 69.5% (1,685/2,424) |
| >25 y | 14.6% (480/3,286) | 69.4% (2,864/4,130) |
Fig 3Malaria parasite prevalence by nPCR inside and outside serologically defined hotspots in the study area in Rachuonyo South District during a community survey conducted in June–July 2011.
nPCR-based parasite prevalence is plotted for individuals residing inside 27 serologically defined hotspots (black bars), 1–249 meters from the hotspot boundary (grey hatched bars), 250–500 m from the hotspot boundary (open hatched bars), and >500 meters from the hotspot boundary (open bars). Parasite prevalence by nPCR is shown per altitude band. Error bars indicate the upper limit of the 95% confidence interval; the p-value for the trend test is given, adjusting for correlations between observations from individuals living in the same compound. The number of individuals for whom samples were available for nPCR inside hotspot boundaries was 2,222 individuals (1,350–1,449 m), 2,494 (1,450–1,499 m), 1,348 (1,500–1,549 m), and 118 (1,550–1,650 m). The number of individuals for 1–249 m from hotspot boundaries was 698 (1,350–1,449 m), 1,248 (1,450–1,499 m), 1,113 (1,500–1,549 m), and 246 (1,550–1,650 m). The number of individuals for 250–500 m from hotspot boundaries was 544 (1,350–1,449 m), 681 (1,450–1,499 m), 661 (1,500–1,549 m), and 164 (1,550–1,650 m). The number of individuals for >500 m from hotspot boundaries was 544 (1,350–1,449 m), 176 (1,450–1,499 m), 405 (1,500–1,549 m), and 135 (1,550–1,650 m).
Fig 4Overview of the cluster-randomized trial conducted in Rachuonyo South District in March–September 2012.
Clusters were serologically defined hotspots with a surrounding 500-m evaluation zone and were randomly allocated to the intervention (n = 5) or control arm (n = 5). Cross-sectional surveys were conducted at baseline (22 March–15 April 2012) and at 8 wk (16 June–6 July 2012) and 16 wk after the intervention (21 August–10 September 2012). In each survey, 25 compounds were randomly selected from within hotspots and 50 from the surrounding evaluation zone (25 compounds 1–249 m from the hotspot boundary and 25 compounds 250–500 m from the hotspot boundary). In intervention hotspots, data were available for all compounds at baseline and were therefore included in the analysis. If selected compounds were not inhabited or compound members were absent, the nearest non-selected inhabited compound was selected as a replacement. Compounds were not revisited before replacements were sought. fMDA, focal MDA.
Cluster-randomized trial baseline characteristics (March–April 2012) and intervention coverage within control and intervention hotspots in Rachuonyo South District.
| Characteristic | Intervention Hotspots | Control Hotspots | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hotspot 4 | Hotspot 6 | Hotspot 7 | Hotspot 8 | Hotspot 10 | Average | Hotspot 1 | Hotspot 2 | Hotspot 3 | Hotspot 5 | Hotspot 9 | Average | |
|
| 120 (631) | 73 (365) | 42 (233) | 58 (282) | 109 (571) | 80 (416) | 30 (135) | 27 (133) | 26 (119) | 25 (122) | 26 (131) | 27 (128) |
|
| 1,396–1,424 | 1,475–1,499 | 1,450–1,474 | 1,500+ | 1,425–1,449 | 1,450–1,474 | 1,350–1,449 | 1,350–1,449 | 1,500–1,549 | 1,450–1,499 | 1,500–1,549 | 1,450–1,499 |
|
| 403 | 239 | 239 | 398 | 257 | 316 | 448 | 271 | 618 | 569 | 510 | 479 |
|
| 19.3 (122/630) | 20.1 (73/364) | 16.8 (39/232) | 11.7 (33/ 281) | 39.0 (222/570) | 23.5 (489/2,077) | 12.6 (17/135) | 21.1 (28/133) | 6.7 (8/119) | 30.3 (37/122) | 22.1 (29/131) | 18.6 (119/640) |
|
| 94.5 (120/127) | 96.2 (76/79) | 97.7 (43/44) | 98.3 (58/59) | 96.6 (114/118) | 96.3 (411/427) | — | — | — | — | — | — |
|
| ||||||||||||
| Use before intervention | 73.1 (440/602) | 71.8 (227/316) | 69.3 (142/205) | 53.4 (142/266) | 77.4 (425/549) | 71.5 (1,385/1,938) | 77.1 (101/131) | 75.4 (86/114) | 73.0 (84/115) | 82.8 (101/122) | 59.4 (73/123) | 73.6 (445/605) |
| Use after intervention | 95.7 (135/141) | 94.2 (129/137) | 94.5 (120/127) | 96.0 (119/124) | 97.1 (168/173) | 95.6 (671/702) | 90.3 (121/134) | 84.4 (108/128) | 93.7 (163/174) | 77.6 (97/125) | 66.0 (95/144) | 82.8 (584/705) |
|
| 90.7 (421/464) | 89.8 (255/284) | 97.5 (154/158) | 93.4 (198/212) | 89.2 (379/425) | 91.2 (1,407/1,543) | 74.1 (80/108) | 81.4 (79/97) | 67.0 (63/94) | 70.0 (63/90) | 62.8 (59/94) | 71.2 (344/483) |
|
| ||||||||||||
| Compounds participating in screening, percent ( | 93.8 (121/129) | 93.7 (74/79) | 100 (44/44) | 96.7 (58/60) | 90.8 (109/120) | 94.0 (406/432) | — | — | — | — | — | — |
| Compounds with ≥1 RDT-positive inhabitant, percent ( | 42.1 (51/121) | 34.2 (25/73) | 33.3 (14/42) | 14.0 (8/57) | 66.1 (72/109) | 42.3 (170/402) | — | — | — | — | — | — |
| Members of eligible compounds who completed treatment, percent ( | 91.5 (301/329) | 97.5 (155/159) | 91.3 (94/103) | 95.8 (46/48) | 97.2 (419/431) | 94.9 (1,015/1,070) | — | — | — | — | — | — |
Coverage with LLINs was defined as percentage of respondents reporting sleeping under a LLIN the night before the survey. Coverage of IRS was defined as the proportion of successfully sprayed sleeping spaces and was assessed in all compounds in the intervention hotspots and a random selection of compounds in control hotspots during the June–July 2012 survey. Coverage with the focal MDA campaign was defined as the proportion of compounds that participated in the screening of sentinel populations by RDT that prompted treatment, the proportion of compounds with ≥1 RDT-positive inhabitant that were therefore eligible for MDA, and the proportion of the members of these eligible compounds who completed six doses of treatment, of which the morning doses (dose 1, 3, and 5) were observed and the afternoon doses were given without supervision but blisters were checked.
The impact of the combined targeted interventions on nPCR malaria parasite prevalence, complexity of infection, and allelic richness in hotspots and evaluation zones.
| Time Point | Group or Value | nPCR Parasite Prevalence (95% CI) | Mean Number of Clones (95% CI) | Mean Complexity of Infection (95% CI) | Mean Allelic Richness | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hotspot | Evaluation Zone | Hotspot | Evaluation Zone | Hotspot | Evaluation Zone | Hotspot | Evaluation Zone | ||||||
| 1–249 m | 250–500 m | 1–249 m | 250–500 m | 1–249 m | 250–500 m | 1–249 m | 250–500 m | ||||||
|
| Intervention | 20.1 (6.3 to 33.9) | 13.2 (7.1 to 19.4) | 13.5 (7.6 to 19.4) | 0.45 (0.04 to 0.85) | 0.28 (0.14 to 0.42) | 0.30 (0.15 to 0.44) | 2.12 (1.65 to 2.60) | 2.15 (1.67 to 2.63) | 2.24 (1.14 to 3.33) | 16.3 | 18.3 | 12.4 |
| Control | 18.6 (7.2 to 29.9) | 11.7 (6.0 to 17.4) | 16.9 (2.3 to 31.5) | 0.45 (0.22 to 0.68) | 0.28 (0.16 to 0.39) | 0.43 (0.08 to 0.78) | 2.64 (1.75 to 3.52) | 2.50 (2.08 to 2.93) | 2.74 (1.72 to 3.76) | 17.0 | 16.3 | 11.4 | |
|
| Intervention | 9.2 (4.4 to 14.0) | 12.3 (9.8 to 14.8) | 9.1 (4.3 to 13.9) | 0.24 (0.11 to 0.36) | 0.30 (0.14 to 0.45) | 0.29 (0.05 to 0.53) | 2.70 (2.04 to 3.35) | 2.46 (1.81 to 3.12) | 2.98 (0.73 to 5.24) | 15.4 | 18.0 | 6.1 |
| Control | 19.4 (6.5 to 32.3) | 15.9 (8.9 to 22.9) | 12.9 (7.1 0 18.7) | 0.41 (0.00 to 0.85) | 0.35 (0.16 to 0.54) | 0.30 (0.17 to 0.43) | 2.08 (1.39 to 2.76) | 2.45 (2.08 to 2.83) | 2.34 (1.60 to 3.09) | 18.6 | 20.2 | 6.8 | |
| Difference | 10.2 (−1.3 to 21.7) | 3.6 (−2.6 to 9.7) | 3.8 (−2.4 to 10.0) | 0.17 (−0.19 to 0.55) | 0.05 (−0.15 to 0.26) | 0.01 (−0.21 to 0.23) | −0.62 (−1.41 to 0.17) | −0.01 (−0.64 to 0.62) | −0.64 (−2.61 to 1.33) | ||||
|
| 0.075 | 0.219 | 0.199 | 0.307 | 0.560 | 0.923 | 0.110 | 0.968 | 0.475 | 0.230 | 0.202 | 0.239 | |
| Adjusted | 0.024 | 0.216 | 0.187 | 0.170 | 0.530 | 0.792 | 0.058 | 0.962 | 0.552 | ||||
|
| Intervention | 10.1 (3.2 to 17.1) | 11.4 (2.6 to 20.1) | 9.8 (2.6 to 17.1) | 0.19 (0.02 to 0.35) | 0.26 (0.04 to 0.49) | 0.23 (0.13 to 0.33) | 1.76 (1.12 to 2.40) | 2.33 (1.78 to 2.88) | 2.57 (1.48 to 3.76) | 11.5 | 19.7 | 10.5 |
| Control | 14.5 (5.4 to 23.5) | 12.4 (8.2 to 16.6) | 10.8 (2.2 to 19.5) | 0.29 (0.13 to 0.46) | 0.27 (0.16 to 0.37) | 0.24 (0.00 to 0.49) | 2.06 (1.67 to 2.45) | 2.13 (1.92 to 2.34) | 2.06 (1.59 to 2.52) | 12.9 | 18.9 | 10.3 | |
| Difference | 4.2 (−5.1 to 13.8) | 1.0 (−7.0 to 9.1) | 1.0 (−8.3 to 10.4) | 0.11 (−0.09 to 0.30) | 0.00 (−0.20 to 0.21) | 0.01 (−0.22 to 0.23) | 0.30 (−0.32 to 0.92) | −0.20 (−0.69 to 0.29) | −0.52 (−1.51 to 0.47) | ||||
|
| 0.326 | 0.775 | 0.804 | 0.248 | 0.980 | 0.933 | 0.274 | 0.380 | 0.261 | 0.217 | 0.679 | 0.844 | |
| Adjusted | 0.265 | 0.713 | 0.809 | 0.375 | 0.990 | 0.625 | 0.375 | 0.615 | 0.379 | ||||
At baseline (March 2012), the standard deviation of nPCR prevalence in hotspots was 9.6, and the observed coefficient of variation was therefore 0.50.
*Including all nPCR-positive and -negative results.
¥Including only nPCR-positive individuals.
§Adjusted for baseline malaria prevalence, age, sex, altitude, and living in a house with open eaves.
Fig 5Indoor densities of female anophelines by light trap in intervention and control clusters in Rachuonyo South District in March–August 2012.
Each symbol represents the number of female anophelines caught indoors by CDC light trap inside hotspots (filled circles) and in evaluation zones (open circles). Each trap night, four compounds were randomly selected within the hotspot and eight were selected in the evaluation zone per cluster. Findings are summarized for trapping rounds prior to roll-out of interventions in 22 March–30 April 2012 (one trapping night per compound) and post-intervention in 1 May–30 June 2012 (three trapping nights per compound) and 1 July–31 August 2012 (five trapping nights per compound). Findings are presented for three intervention clusters combined and for three control clusters combined.